Rho-associated kinase (ROCK, pan)

Class

Pan-ROCK inhibitor

Rho-associated kinase (ROCK) is a serine/threonine kinase that acts downstream of the small GTPase RhoA, a master switch controlling the cytoskeleton of many cell types. By phosphorylating substrates that regulate the actin-myosin contractile machinery, ROCK governs how cells adhere, contract, migrate, and proliferate. Two closely related isoforms, ROCK1 and ROCK2, are expressed throughout the body, including in vascular smooth muscle, ocular tissue, fibroblasts, and immune cells. A pan-ROCK inhibitor blocks both isoforms simultaneously, producing broad effects on smooth muscle relaxation and connective tissue remodeling rather than the narrower profile an isoform-selective agent might achieve. This mechanism is relevant wherever excessive cytoskeletal tension or fibrotic tissue remodeling drives disease: elevated eye pressure in glaucoma, vasospasm in cerebral or coronary arteries, pulmonary and systemic hypertension, and fibrotic scarring in lung, kidney, or liver disease. Because RhoA-ROCK signaling also participates in normal vascular tone and wound healing, inhibiting it broadly can shift blood pressure and tissue repair processes throughout the body, not only at the diseased site. The rationale for pursuing a pan-ROCK approach rests on the idea that many of these pathological processes involve both isoforms acting in parallel or redundantly, so blocking only one may leave compensatory signaling intact.